The global AI in cardiology market size was estimated at USD 1.69 billion in 2025 and is projected to reach USD 14.83 billion by 2033, growing at a CAGR of 31.17% from 2026 to 2033. The rising global prevalence of cardiovascular diseases, coupled with the increasing focus of cardiac specialists on enhancing diagnostic precision and rapid advancements in cardiac imaging technology, are among the key factors responsible for expanding the applications of AI in cardiology.
For instance, in May 2023, Sensydia announced the development of its Cardiac Performance System (CPS), which uses biosensors and AI to detect heart abnormalities. The company secured USD 8 million in funding to advance its technology.
A primary factor driving the growth of the artificial intelligence in cardiology industry is the increasing prevalence of cardiovascular diseases (CVDs) and the consequent need for efficient & effective healthcare solutions. According to the WHO, CVD remains the leading cause of mortality worldwide. For instance, an estimated 19.8 million people died from CVDs in 2022, representing approximately 32% of all global deaths. Similarly, according to the Centers for Disease Control and Prevention (CDC), 919,032 people died from cardiovascular disease in the U.S. in 2023, equivalent to one in every three deaths. This escalating burden necessitates the development and implementation of advanced technologies to improve disease management and patient outcomes.
The high prevalence of conditions such as hypertension, coronary artery disease, heart failure, and arrhythmia puts a substantial strain on healthcare systems globally. Traditional diagnostic & treatment methods are often time-consuming & resource-intensive and are likely to lack the precision required for optimal patient care. AI offers a transformative solution by enhancing the accuracy and efficiency of CVD detection, diagnosis, and management.
Moreover, the integration of AI in cardiology facilitates the delivery of personalized medicine. By analyzing individual patient data, AI helps tailor treatment plans to address the unique needs and conditions of each patient. For instance, in managing heart failure, AI helps determine the most effective combination of medications and lifestyle modifications for each patient based on their specific disease profile and response to previous treatments. This personalized approach enhances the efficacy of interventions and improves patients' overall quality of life.
Technological advancements in AI algorithms and imaging techniques significantly drive the market growth. The development of advanced machine learning and deep learning algorithms has revolutionized the capabilities of AI in medical imaging and diagnostics. These advanced algorithms can now process vast amounts of data with high precision, allowing early detection, accurate diagnosis, and personalized treatment plans for CVDs. For instance, in June 2024, UltraSight partnered with Mayo Clinic to advance AI-driven cardiac imaging solutions. The collaboration focuses on developing algorithms that enhance point-of-care ultrasound for cardiac assessments. Similarly, in February 2025, Heart Eye Diagnostics developed Dr.Noon CVD, an AI-driven retinal imaging system for cardiovascular disease (CVD) risk assessment. Using noninvasive retinal images instead of CT or blood tests, it offers accuracy comparable to heart CT scans and delivers results in three minutes.
In addition,the growth of AI in cardiology market is significantly propelled by the rise in strategic initiatives and the surge in startup funding. Strategic initiatives, including partnerships, new launches, collaborations, & acquisitions, foster innovation and accelerate the development & deployment of AI solutions in cardiology. For instance, in May 2024, iHridAI launched its novel, innovative product, HarmonyCVI, designed for thorough and precise cardiovascular diagnosis. HarmonyCVI is an advanced diagnostic and analysis tool that utilizes AI & machine learning to assist cardiologists and radiologists in the improved interpretation of cardiac MRI scans. Similarly, in September 2024, Abbott partnered with iCardio.ai to develop artificial intelligence imaging solutions to improve cardiovascular diagnostics. These initiatives are often aimed at integrating AI with existing healthcare infrastructure to enhance diagnostic accuracy and improve patient outcomes.
This product will be delivered within 1-3 business days.
For instance, in May 2023, Sensydia announced the development of its Cardiac Performance System (CPS), which uses biosensors and AI to detect heart abnormalities. The company secured USD 8 million in funding to advance its technology.
A primary factor driving the growth of the artificial intelligence in cardiology industry is the increasing prevalence of cardiovascular diseases (CVDs) and the consequent need for efficient & effective healthcare solutions. According to the WHO, CVD remains the leading cause of mortality worldwide. For instance, an estimated 19.8 million people died from CVDs in 2022, representing approximately 32% of all global deaths. Similarly, according to the Centers for Disease Control and Prevention (CDC), 919,032 people died from cardiovascular disease in the U.S. in 2023, equivalent to one in every three deaths. This escalating burden necessitates the development and implementation of advanced technologies to improve disease management and patient outcomes.
The high prevalence of conditions such as hypertension, coronary artery disease, heart failure, and arrhythmia puts a substantial strain on healthcare systems globally. Traditional diagnostic & treatment methods are often time-consuming & resource-intensive and are likely to lack the precision required for optimal patient care. AI offers a transformative solution by enhancing the accuracy and efficiency of CVD detection, diagnosis, and management.
Moreover, the integration of AI in cardiology facilitates the delivery of personalized medicine. By analyzing individual patient data, AI helps tailor treatment plans to address the unique needs and conditions of each patient. For instance, in managing heart failure, AI helps determine the most effective combination of medications and lifestyle modifications for each patient based on their specific disease profile and response to previous treatments. This personalized approach enhances the efficacy of interventions and improves patients' overall quality of life.
Technological advancements in AI algorithms and imaging techniques significantly drive the market growth. The development of advanced machine learning and deep learning algorithms has revolutionized the capabilities of AI in medical imaging and diagnostics. These advanced algorithms can now process vast amounts of data with high precision, allowing early detection, accurate diagnosis, and personalized treatment plans for CVDs. For instance, in June 2024, UltraSight partnered with Mayo Clinic to advance AI-driven cardiac imaging solutions. The collaboration focuses on developing algorithms that enhance point-of-care ultrasound for cardiac assessments. Similarly, in February 2025, Heart Eye Diagnostics developed Dr.Noon CVD, an AI-driven retinal imaging system for cardiovascular disease (CVD) risk assessment. Using noninvasive retinal images instead of CT or blood tests, it offers accuracy comparable to heart CT scans and delivers results in three minutes.
In addition,the growth of AI in cardiology market is significantly propelled by the rise in strategic initiatives and the surge in startup funding. Strategic initiatives, including partnerships, new launches, collaborations, & acquisitions, foster innovation and accelerate the development & deployment of AI solutions in cardiology. For instance, in May 2024, iHridAI launched its novel, innovative product, HarmonyCVI, designed for thorough and precise cardiovascular diagnosis. HarmonyCVI is an advanced diagnostic and analysis tool that utilizes AI & machine learning to assist cardiologists and radiologists in the improved interpretation of cardiac MRI scans. Similarly, in September 2024, Abbott partnered with iCardio.ai to develop artificial intelligence imaging solutions to improve cardiovascular diagnostics. These initiatives are often aimed at integrating AI with existing healthcare infrastructure to enhance diagnostic accuracy and improve patient outcomes.
Case Study Insights: Accelerating Surgical Navigation through Ai-Driven Chest Ct Segmentation by RSIP Vision
RSIP Vision developed an advanced AI-based solution to automatically generate high-resolution 3D models of complex, patient-specific chest anatomies from CT scans. These models are crucial for planning intricate surgical navigation procedures, where precise anatomical visualization informs safer and more effective interventions. Conventional solutions were slow, lacked robustness, and required extensive manual editing, burdening clinical workflows.Global AI In Cardiology Market Report Segmentation
This report forecasts revenue growth and provides at the global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. The report has segmented the global AI in cardiology market report based on component, application, medical condition, and region:Component Outlook (Revenue, USD Million, 2021-2033)
- Software
- Hardware
- Services
Application Outlook (Revenue, USD Million, 2021-2033)
- Diagnosis
- Prediction
- Drug Discovery
- Others
Medical Condition Outlook (Revenue, USD Million, 2021-2033)
- Cardiac Arrhythmias
- Heart Failure
- Ischemic Heart Disease /CAD
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Artificial Intelligence in Cardiology Market Variables, Trends & Scope
Chapter 4. Artificial Intelligence in Cardiology Market: Component Estimates & Trend Analysis
Chapter 5. Artificial Intelligence in Cardiology Market: Application Estimates & Trend Analysis
Chapter 6. Artificial Intelligence in Cardiology Market: Medical Condition Estimates & Trend Analysis
Chapter 7. Artificial Intelligence in Cardiology Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this AI in Cardiology market report include:- GE Healthcare
- Heartflow, Inc.
- IDOVEN
- CardiAI
- Ultromics Limited
- Arterys Inc. (Tempus AI)
- Ultrasight
- Koninklijke Philips N.V.
- Vista AI
- Viz.ai, Inc.
- RSIP Vision
- Cleerly, Inc.
- Medical AI Co., Ltd.
- anumana, Inc.
- Aidoc
- Circle Cardiovascular Imaging Inc.
- Eko Health, Inc.
- cardiomatics.com
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | December 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 1.69 Billion |
| Forecasted Market Value ( USD | $ 14.83 Billion |
| Compound Annual Growth Rate | 31.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 19 |
